January 9, 2018 / 1:36 AM / a year ago

BRIEF-Astellas Pharma says application of marketing approval for blinatumomab in Japan

Jan 9 (Reuters) - Astellas Pharma Inc

* Says it announced that an application was submitted in Japan for the marketing authorization for bispecific CD19-directed CD3 T cell engager (BiTE®) antibody construct blinatumomab to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia

* In Japan, blinatumomab is jointly developed by Amgen Astellas BioPharma and the co

Source text in Japanese: goo.gl/iGVamQ

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below